home

 
   
  ESSIC  

- who are we?

 

- membership

 

- meeting reports

 
   
  topics  

- BPS definition and diagnosis

 
- Hunner lesion  
- disease activity and damage  
- video's of cystoscopies  
   
  literature  

- new

 

- treatment

 
- diagnostic criteria  
- Hunner lesion  

- associated diseases

 
- confusable diseases  

- selected topics & books

 
- symptom score questionnaires  

- reports from other sources

 
   
  various  

- calendar

 

- useful links

 

- support organizations

 

- disclaimer

 
literature on randomized placebo-controlled trials with a beneficial effect (under construction)  
     

ESSIC uses the name bladder pain syndrome (BPS) instead of interstitial cystitis (IC) and/or painful bladder syndrome (PBS):
click here
for more details.

 

 
     
this section is divided into: oral treatment  
  intravesical treatment  
  other treatments  
     
oral treatment  
   
 
  • Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis.
    Nickel JC, Barkin J, Forrest J, et al. Urology 2005;65:654-8
    three dosages (300, 600, and 900 mg) of PPS in a randomized, double-blind, double-dummy, parallel-group, multicenter, 32-week study were studied in 380 IC patients
    at study end, 27.5%, 56.9%, and 15.7% reported mild, moderate, and severe symptoms, respectively
    • for all three dosages of PPS, a clinically significant but similar response was demonstrated; the duration of therapy appears to be more important than the dosage
   
intravesical treatment  
   
 
  • Safety and Efficacy of the Use of Intravesical and Oral Pentosan Polysulfate Sodium for Interstitial Cystitis: A Randomized Double-Blind Clinical Trial.
    Davis EL, El Khoudary SR, Talbott EO, et al. J Urol 2007 Nov 12; [Epub ahead of print]
    • 41 females diagnosed with IC were randomized to receive a combination of intravesical pentosan polysulfate sodium plus oral pentosan polysulfate sodium or intravesical placebo plus oral pentosan polysulfate sodium for 6 weeks; all subjects continued to receive oral pentosan polysulfate sodium for another 12 weeks
    • at week 18 the treatment group showed statistically significant improvement in all quality of life scores, while the placebo group showed significant improvement in only 3 quality of life scores compared to the baseline
 
   
other treatments  
   
     
     
     
     
  © 2004-2017 ESSIC - International Society for the Study of Bladder Pain Syndrome  
05.02.2008 16:37